Exploring potential therapeutic agents for lipopolysaccharide-induced septic cardiomyopathy based on transcriptomics using bioinformatics

• Published in: Scientific reports 2023-11, Vol.13 (1), p.20589-20589, Article 20589
• Main Authors: Feng, Shaodan, Cai, Kexin, Lin, Siming, Chen, Xiaojun, Luo, Yuqing, Wang, Jing, Lian, Guili, Lin, Zhihong, Xie, Liangdi
• Format: Article
• Language: English
• Subjects: 631/114; 631/250; 692/4019; 692/420; 692/53; Animals; Bioinformatics; Cardiomyopathies - chemically induced; Cardiomyopathies - drug therapy; Cardiomyopathy; Chemokines; Computational Biology; Congestive heart failure; Cytokines; Drug development; Gene Expression Profiling; Genes; Genomes; Humanities and Social Sciences; Lipopolysaccharides; Lipopolysaccharides - adverse effects; MAP kinase; MicroRNAs - genetics; multidisciplinary; Pathogenesis; Rac2 protein; Rats; Science; Science (multidisciplinary); Sepsis; Signal transduction; Transcriptome; Transcriptomics; Ventricle
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-023-47699-0

Septic cardiomyopathy (SCM) is a common and severe complication of sepsis, characterized by left ventricular dilation and reduced ejection fraction leading to heart failure. The pathogenesis of SCM remains unclear. Understanding the SCM pathogenesis is essential in the search for effective therapeutic agents for SCM. This study was to investigate the pathophysiology of SCM and explore new therapeutic drugs by bioinformatics. An SCM rat model was established by injection of 10 mg/kg lipopolysaccharide (LPS) for 24 h, and the myocardial tissues were collected for RNA sequencing. The differentially expressed genes (DEGs) between LPS rats and control (Ctrl) with the thresholds of |log2 fold change |≥ 1 and P